Gene Therapy for Duchenne Muscular Dystrophy


Duchenne muscular dystrophy is a severe muscle wasting disorder caused by lack of functional dystrophin, due to reading‐frame disrupting mutations in the DMD gene. There is no cure, but several genetic therapeutic approaches aiming to delay disease progression by restoring, manipulating or replacing the DMD gene are under investigation in (pre)clinical settings. The antisense‐mediated exon skipping approach, which restores the disrupted reading frame allowing synthesis of partly functional dystrophin proteins is closest to clinical application. The first trials with viral vectors to deliver minidystrophin genes and compounds to force readthrough of premature stop codons by the translation machinery have also been undertaken, whereas other approaches, like genome editing, are still in the early development phase. Despite some remaining hurdles that have to be overcome, lessons learned can be used to catalyse the development of potential therapies.

Key Concepts:

  • Duchenne muscular dystrophy (DMD) is caused by reading‐frame disrupting mutations in the DMD gene, resulting in premature termination of dystrophin synthesis.

  • Inframe mutations allow synthesis of shorter, but partly functional dystrophin proteins, resulting in the milder Becker muscular dystrophy (BMD) phenotype.

  • Antisense oligonucleotide‐mediated exon skipping aims to restore the reading frame enabling synthesis of BMD‐like dystrophins, thereby converting the severe DMD into the milder BMD disease.

  • Gene replacement therapy (replacing the dysfunctional dystrophin cDNA) is hampered by the size and complexity of the DMD gene and dystrophin cDNA.

  • AAV vectors have a limited loading capacity of ∼4.5 kb, requiring the use of mini‐, or microdystrophin genes that encode only the most crucial functional domains.

  • Ataluren can be used to force the translational machinery to ignore premature stop codons enabling synthesis of intact dystrophin.

  • Endonuclease‐mediated generation of double‐strand breaks can be used to correct the genetic mutation or restore the reading frame.

  • Many therapeutic approaches have progressed to clinical trials.

Keywords: duchenne muscular dystrophy; gene therapy; dystrophin; exon skipping; antisense oligonucleotide; adeno‐associated viruses; readthrough of premature stop codons; genome editing

Figure 1.

(a) In healthy individuals, pre‐mRNA is converted into mRNA by the splicing machinery, which is translated into full‐length dystrophin. (b) Example of a DMD patient with a deletion of exons 52–58, which disrupts the reading frame and prevents translation of the complete dystrophin protein. (c) AONs targeting exon 51 hide this exon from the splicing machinery so that it is spliced out together with the flanking introns. This restores the reading frame so that a BMD‐like dystrophin protein can be generated.

Figure 2.

(a) Schematic overview of the full‐length dystrophin protein, which consists of four domains. At the N‐terminus, it has an actin‐binding domain 1 (A‐BD1), followed by the central rod domain that contains four proline‐rich hinge regions (H1–4) and 24 spectrin‐like repeats. Within the rod domain, a second actin‐binding domain (A‐BD2) and an nNOS‐binding domain (nNOS BD) are present located between repeats 11–17 and 16–17, respectively. The C‐terminal part consists of three binding domains for β‐dystroglycan (Dg‐BD), α‐sarcoglycan (S‐BD) and α‐dystrobrevin (Db‐BD). (b) The rAAV2.5‐CMV‐mini‐dystrophin protein, used for the clinical trial by Bowles et al. , contains the first actin‐binding domain, three hinge regions, five spectrin‐like repeats and the β‐dystroglycan‐binding domain.

Figure 3.

(a) Example of a DMD patient with a stop codon (UAG) mutation in exon 9 resulting in premature termination of protein translation. (b) Administration of ataluren/PTC124 ensures readthrough of the translational machinery ignoring the premature stop codon enabling synthesis of full‐length dystrophin.

Figure 4.

(a) Genome editing can be used to restore a point mutation (indicated by star) in the DMD gene using a nuclease to induce a specific double‐stranded DNA break and a wild‐type template (pink). Once the mutation has been corrected, synthesis of full‐length dystrophin is feasible. (b) Deletions (or duplications) that disrupt the reading frame (indicated by star) can also be repaired by genome editing. Either the exon splice site or the mutation can be targeted. When the splice site (of the exon containing the mutation) is targeted by double‐strand breaks one or multiple base pairs are inserted or deleted, thereby abolishing the splice site, leading to skipping of the exon. Alternatively, when the mutation is targeted directly a random number of nucleotides is included or deleted, which restore the reading frame in ∼1:3 of cases. Exon skipping and reading frame restoration will both lead to internally deleted, BMD‐like dystrophin proteins.



Aartsma‐Rus A, Fokkema I, Verschuuren J et al. (2009) Theoretic applicability of antisense‐mediated exon skipping for Duchenne muscular dystrophy mutations. Human Mutation 30: 293–299.

Abdel‐Hamid H and Clemens PR (2012) Pharmacological therapies for muscular dystrophies. Current Opinion in Neurology 25: 604–608.

Alter J, Lou F, Rabinowitz A et al. (2006) Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nature Medicine 12: 175–177.

Barton‐Davis ER, Cordier L, Shoturma DI, Leland SE and Sweeney HL (1999) Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. Journal of Clinical Investigation 104: 375–381.

Blake DJ, Weir A, Newey SE and Davies KE (2002) Function and genetics of dystrophin and dystrophin‐related proteins in muscle. Physiological Reviews 82: 291–329.

Bostick B, Shin JH, Yue Y and Duan D (2011) AAV‐microdystrophin therapy improves cardiac performance in aged female mdx mice. Molecular Therapeutics 19: 1826–1832.

Bowles DE, McPhee SW, Li C et al. (2012) Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Molecular Therapeutics 20: 443–455.

Burke JF and Mogg AE (1985) Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G‐418 and paromomycin. Nucleic Acids Research 13: 6265–6272.

Bushby K, Finkel R, Birnkrant DJ et al. (2010) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurology 9: 77–93.

Cazzella V, Martone J, Pinnaro C et al. (2012) Exon 45 skipping through U1‐snRNA antisense molecules recovers the Dys‐nNOS pathway and muscle differentiation in human DMD myoblasts. Molecular Therapeutics 20: 2134–2142.

Chapdelaine P, Pichavant C, Rousseau J, Paques F and Tremblay JP (2010) Meganucleases can restore the reading frame of a mutated dystrophin. Gene Therapy 17: 846–858.

Cirak S, Arechavala‐Gomeza V, Guglieri M et al. (2011) Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open‐label, phase 2, dose‐escalation study. Lancet 378: 595–605.

Daboussi F, Zaslavskiy M, Poirot L et al. (2012) Chromosomal context and epigenetic mechanisms control the efficacy of genome editing by rare‐cutting designer endonucleases. Nucleic Acids Research 40: 6367–6379.

De Angelis FG, Sthandier O, Berarducci B et al. (2002) Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre‐mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48‐50 DMD cells. Proceedings of the National Academy of Sciences of the USA 99: 9456–9461.

van Deutekom JC, Bremmer‐Bout M, Janson AA et al. (2001) Antisense‐induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Human Molecular Genetics 10: 1547–1554.

van Deutekom JC, Janson AA, Ginjaar IB et al. (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. New England Journal of Medicine 357: 2677–2686.

Dunant P, Walter MC, Karpati G and Lochmuller H (2003) Gentamicin fails to increase dystrophin expression in dystrophin‐deficient muscle. Muscle and Nerve 27: 624–627.

Dunckley MG, Manoharan M, Villiet P, Eperon IC and Dickson G (1998) Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Human Molecular Genetics 7: 1083–1090.

Emery AE (2002) The muscular dystrophies. Lancet 359: 687–695.

England SB, Nicholson LV, Johnson MA et al. (1990) Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 343: 180–182.

Ervasti JM (2007) Dystrophin, its interactions with other proteins, and implications for muscular dystrophy. Biochimica et Biophysica Acta 1772: 108–117.

Fan Z, Kocis K, Valley R et al. (2012) Safety and feasibility of high‐pressure transvenous limb perfusion with 0.9% saline in human muscular dystrophy. Molecular Therapeutics 20: 456–461.

Ferrer A, Wells KE and Wells DJ (2000) Immune responses to dystropin: implications for gene therapy of Duchenne muscular dystrophy. Gene Therapy 7: 1439–1446.

Finkel RS (2010) Read‐through strategies for suppression of nonsense mutations in Duchenne/Becker muscular dystrophy: aminoglycosides and ataluren (PTC124). Journal of Child Neurology 25: 1158–1164.

Foster H, Popplewell L and Dickson G (2012) Genetic therapeutic approaches for Duchenne muscular dystrophy. Human Gene Therapy 23: 676–687.

Goemans NM, Tulinius M, van den Akker JT et al. (2011) Systemic administration of PRO051 in Duchenne's muscular dystrophy. New England Journal of Medicine 364: 1513–1522.

Goyenvalle A, Babbs A, Wright J et al. (2012a) Rescue of severely affected dystrophin/utrophin‐deficient mice through scAAV‐U7snRNA‐mediated exon skipping. Human Molecular Genetics 21: 2559–2571.

Goyenvalle A, Vulin A, Fougerousse F et al. (2004) Rescue of dystrophic muscle through U7 snRNA‐mediated exon skipping. Science 306: 1796–1799.

Goyenvalle A, Wright J, Babbs A et al. (2012b) Engineering multiple U7snRNA constructs to induce single and multiexon‐skipping for Duchenne muscular dystrophy. Molecular Therapeutics 20: 1212–1221.

Gregorevic P, Allen JM, Minami E et al. (2006) rAAV6‐microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nature Medicine 12: 787–789.

Gregorevic P, Blankinship MJ, Allen JM et al. (2004) Systemic delivery of genes to striated muscles using adeno‐associated viral vectors. Nature Medicine 10: 828–834.

Heemskerk H, de Winter CL, van Kuik P et al. (2010) Preclinical PK and PD studies on 2′‐O‐methyl‐phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Molecular Therapeutics 18: 1210–1217.

Hoffman EP, Bronson A, Levin AA et al. (2011) Restoring dystrophin expression in duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through. American Journal of Pathology 179: 12–22.

Hoffman EP, Brown RH Jr. and Kunkel LM (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51: 919–928.

Howard MT, Anderson CB, Fass U et al. (2004) Readthrough of dystrophin stop codon mutations induced by aminoglycosides. Annals of Neurology 55: 422–426.

Ishizaki M, Maeda Y, Kawano R et al. (2011) Rescue from respiratory dysfunction by transduction of full‐length dystrophin to diaphragm via the peritoneal cavity in utrophin/dystrophin double knockout mice. Molecular Therapeutics 19: 1230–1235.

Kayali R, Ku JM, Khitrov G et al. (2012) Read‐through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy. Human Molecular Genetics 21: 4007–4020.

Kinali M, Arechavala‐Gomeza V, Feng L et al. (2009) Local restoration of dystrophin expression with the morpholino oligomer AVI‐4658 in Duchenne muscular dystrophy: a single‐blind, placebo‐controlled, dose‐escalation, proof‐of‐concept study. Lancet Neurology 8: 918–928.

Klein CJ, Coovert DD, Bulman DE et al. (1992) Somatic reversion/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame‐restoring mechanism in rare dystrophin‐positive fibers. American Journal of Human Genetics 50: 950–959.

Love DR, Forrest SM, Smith TJ et al. (1989) Molecular analysis of Duchenne and Becker muscular dystrophies. British Medical Bulletin 45: 659–680.

Malerba A, Boldrin L and Dickson G (2011a) Long‐term systemic administration of unconjugated morpholino oligomers for therapeutic expression of dystrophin by exon skipping in skeletal muscle: implications for cardiac muscle integrity. Nucleic Acid Therapeutics 21: 293–298.

Malerba A, Sharp PS, Graham IR et al. (2011b) Chronic systemic therapy with low‐dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice. Molecular Therapeutics 19: 345–354.

Malik V, Rodino‐Klapac LR and Viollet L (2010) Gentamicin‐induced readthrough of stop codons in Duchenne muscular dystrophy. Annals of Neurology 67: 771–780.

Mendell JR, Campbell K, Rodino‐Klapac L et al. (2010) Dystrophin immunity in Duchenne's muscular dystrophy. New England Journal of Medicine 363: 1429–1437.

Moulton HM, Wu B, Jearawiriyapaisarn N et al. (2009) Peptide‐morpholino conjugate: a promising therapeutic for Duchenne muscular dystrophy. Annals of the New York Academy of Sciences 1175: 55–60.

Odom GL, Gregorevic P, Allen JM and Chamberlain JS (2011) Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6. Molecular Therapeutics 19: 36–45.

Politano L, Nigro G, Nigro V et al. (2003) Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myologica 22: 15–21.

Popplewell L, Koo T, Kymalainen H et al. (2012) Meganuclease‐enhanced genome correction therapy for Duchenne muscular dystrophy. Neuromuscular Disorders 22: S9.

Rousseau J, Chapdelaine P, Boisvert S et al. (2011) Endonucleases: tools to correct the dystrophin gene. Journal of Gene Medicine 13: 522–537.

Schinkel S, Bauer R, Bekeredjian R et al. (2012) Long‐term preservation of cardiac structure and function after adeno‐associated virus serotype 9‐mediated microdystrophin gene transfer in mdx mice. Human Gene Therapy 23: 566–575.

Skuk D, Goulet M, Roy B et al. (2007) First test of a ‘high‐density injection’ protocol for myogenic cell transplantation throughout large volumes of muscles in a Duchenne muscular dystrophy patient: eighteen months follow‐up. Neuromuscular Disorders 17: 38–46.

Takeshima Y, Wada H, Yagi M et al. (2001) Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient. Brain and Development 23: 788–790.

Thanh LT, Nguyen TM, Helliwell TR and Morris GE (1995) Characterization of revertant muscle fibers in Duchenne muscular dystrophy, using exon‐specific monoclonal antibodies against dystrophin. American Journal of Human Genetics 56: 725–731.

Uchida Y, Maeda Y, Kimura E et al. (2005) Effective repetitive dystrophin gene transfer into skeletal muscle of adult mdx mice using a helper‐dependent adenovirus vector expressing the coxsackievirus and adenovirus receptor (CAR) and dystrophin. Journal of Gene Medicine 7: 1010–1022.

Vulin A, Barthelemy I, Goyenvalle A et al. (2012) Muscle function recovery in golden retriever muscular dystrophy after AAV1‐U7 exon skipping. Molecular Therapeutics 20: 2120–2133.

Wagner KR, Hamed S, Hadley DW et al. (2001) Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Annals of Neurology 49: 706–711.

Welch EM, Barton ER, Zhuo J et al. (2007) PTC124 targets genetic disorders caused by nonsense mutations. Nature 447: 87–91.

Wilton SD, Lloyd F, Carville K et al. (1999) Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscular Disorders 9: 330–338.

Yin H, Moulton HM, Betts C et al. (2010) Functional rescue of dystrophin‐deficient mdx mice by a chimeric peptide‐PMO. Molecular Therapeutics 18: 1822–1829.

Yin H, Moulton HM, Seow Y et al. (2008) Cell‐penetrating peptide‐conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Human Molecular Genetics 17: 3909–3918.

Yin H, Saleh AF, Betts C et al. (2011) Pip5 transduction peptides direct high efficiency oligonucleotide‐mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Molecular Therapeutics 19: 1295–1303.

Further Reading

Aartsma‐Rus A (2010) Antisense‐mediated modulation of splicing: therapeutic implications for Duchenne muscular dystrophy. RNA Biology 7: 453–461.

Goyenvalle A, Seto JT, Davies KE and Chamberlain J (2011) Therapeutic approaches to muscular dystrophy. Human Molecular Genetics 20: R69–R78.

Lai Y and Duan D (2012) Progress in gene therapy of dystrophic heart disease. Gene Therapy 19: 678–685.

Lu QL, Yokota T, Takeda S et al. (2011) The status of exon skipping as a therapeutic approach to duchenne muscular dystrophy. Molecular Therapeutics 19: 9–15.

Mendell JR, Rodino‐Klapac L, Sahenk Z et al. (2012) Gene therapy for muscular dystrophy: lessons learned and path forward. Neuroscience Letters 527: 90–99.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
van Putten, Maaike, and Aartsma‐Rus, Annemieke(Sep 2013) Gene Therapy for Duchenne Muscular Dystrophy. In: eLS. John Wiley & Sons Ltd, Chichester. [doi: 10.1002/9780470015902.a0025029]